Haemonetics (NYSE:HAE) EVP Neil Mr. Ryding sold 267 shares of the stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $46.76, for a total value of $12,484.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Neil Mr. Ryding also recently made the following trade(s):
Get Haemonetics alerts: On Saturday, October 20th, Neil Mr. Ryding sold 351 shares of Haemonetics stock. The shares were sold at an average price of $34.16, for a total value of $11,990.16.Haemonetics traded up $1.60, hitting $90.77, on Wednesday, according to MarketBeat Ratings. 276,400 shares of the company were exchanged, compared to its average volume of 488,215. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.35 and a quick ratio of 0.94. Haemonetics has a 12 month low of $38.47 and a 12 month high of $91.55. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of 48.54, a PEG ratio of 4.11 and a beta of 0.90.
Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.43. Haemonetics had a return on equity of 12.71% and a net margin of 5.04%. The business had revenue of $233.55 million for the quarter, compared to analyst estimates of $226.63 million. During the same period last year, the company earned $0.39 EPS. Haemonetics’s revenue for the quarter was up 2.4% compared to the same quarter last year. sell-side analysts anticipate that Haemonetics will post 2.21 EPS for the current year.
Haemonetics declared that its board has initiated a stock repurchase program on Tuesday, February 6th that authorizes the company to buyback $260.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.
Several equities analysts have recently commented on HAE shares. ValuEngine upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 9th. Morgan Stanley increased their price objective on Haemonetics from $74.00 to $77.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Zacks Investment Research lowered Haemonetics from a “strong-buy” rating to a “sell” rating in a research report on Wednesday, April 11th. JMP Securities reiterated an “outperform” rating and set a $72.00 price objective on shares of Haemonetics in a research report on Wednesday, February 7th. Finally, Barrington Research increased their price objective on Haemonetics to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, May 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $80.83.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Meeder Asset Management Inc. grew its position in Haemonetics by 2,845.3% during the 4th quarter. Meeder Asset Management Inc. now owns 1,885 shares of the medical instruments supplier’s stock worth $110,000 after acquiring an additional 1,821 shares during the last quarter. Alpine Woods Capital Investors LLC bought a new position in Haemonetics during the 1st quarter worth approximately $236,000. CIBC Asset Management Inc bought a new position in Haemonetics during the 4th quarter worth approximately $210,000. Everence Capital Management Inc. bought a new position in Haemonetics during the 4th quarter worth approximately $212,000. Finally, First Allied Advisory Services Inc. bought a new position in Haemonetics during the 4th quarter worth approximately $220,000. Institutional investors and hedge funds own 97.34% of the company’s stock.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.
No comments:
Post a Comment